Article Sidebar

PDF
Date Published: 15/04/2022
Abstract Views: 211
Views PDF: 141
DOI: https://doi.org/10.51298/vmj.v511i1.2034
Issue
Vol. 511 No. 1 (2022)
Section
Các bài báo
How to Cite
Tấn, Đỗ ., Thị Hồng Nhung, N. ., & Thị Thu Thuỷ, P. . (2022). EVALUATION EFFECTIVE OF FIXED-COMBINATION BRINMONIDIN/BRINZOLAMID (SIMBRINZA) IN GLAUCOMA TREATMENT. Vietnam Medical Journal, 511(1). https://doi.org/10.51298/vmj.v511i1.2034

EVALUATION EFFECTIVE OF FIXED-COMBINATION BRINMONIDIN/BRINZOLAMID (SIMBRINZA) IN GLAUCOMA TREATMENT

Đỗ Tấn1, Nguyễn Thị Hồng Nhung1,, Phạm Thị Thu Thuỷ2
1 Central Eye Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Objectives: To evaluate the IOP lowering effect of fixed-combination Simbrinza in glaucoma treatment. Subjects and methodology: The prospective descriptive study. A total of 50 eyes of 30 glaucoma patients over 18 years old where target IOP has not been reached by one antiglaucoma medication. The patients were given a drop of Simbrinza and IOP was taken after 2 hours. If IOP reduction of at least 25% without side effect was achieved then treatment was continued twice a day. The patients were followed up at 1 week, 1 month and 3 months. Results: The mean age of patients were 54,39 ± 15,19 years old. Most patients in age group from 40 to 60 years old accounting for 44%, males accounted for a higher percentage with 58%. The mean IOP decreased from 32,56 ± 10,39 mmHg to 17,8 ± 4,4 mmHg at 2 hours; 16,74 ± 3,89mmHg at 1 week; 16,92 ± 3,18mmHg at 1 month; 16,72 ± 2,91 at 3 months (p < 0,01). IOP reduction at all follow-ups was over 42%. IOP lowering at 2 hours was 42,21% and was highest at 3 months with 43,86%. Rate of IOP complete success was 56% at 2 hours and 56,5% at 3 months. Conclusion: Simbrinza was safe and effective in treating glaucoma with mean IOP lowering of around 42%

Article Details

Keywords

Simbrinza, glaucoma, IOP

References

1. Kumarasamy NA, Lam FS, Wang AL, Theoharides T. Glaucoma: Current and Developing Concepts for Inflammation, Pathogenesis and Treatment. European Journal of Inflammation. 2006;4.
2. Vijaya L, et al. Prevalence and causes of low vision and blindness in an urban population [The Chennai Glaucoma Study. Indian J Ophthalmol] 2014.
3. Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension. Adv Ther. 2014;31(12):1213-1227.
4. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk Factors Associated with the Incidence of Open-Angle Glaucoma: The Visual Impairment Project. Invest Ophthalmol Vis Sci. 2003;44(9):3783-3789.
5. Nguyễn Lê Trung. Đánh giá hiệu quả của thuốc Azarga trong điều trị glôcôm góc mở. 2016. Luận văn Thạc sỹ Y học, Đại học Y Hà Nội
6. Gordon MO. The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma. Arch Ophthalmol. 2002;120(6):714.
7. Vajaranant TS, Nayak S, Wilensky JT, Joslin CE. Gender and glaucoma: what we know and what we need to know. Curr Opin Ophthalmol. 2010;21(2):91-99.
8. Kóthy P, Holló G. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre. Int Ophthalmol. 2020; 40(2):377-383.
9. Iester M. Brinzolamide. Expert Opin Pharmacother. 2008;9(4):653-662.